Follow
'AI-enabled drug discovery has yet to prove itself in the clinic. And on top of that, companies have to worry about intellectual property — regarding not only the drugs but also the discovery methods. “Everybody patents molecules,” says Alex Aliper, the president of Insilico Medicine, headquartered in New York City and Hong Kong. “For algorithms, it’s a choice.”
